PER-030-10已完成未知
A PHASE I/II DOSE-FINDING STUDY OF HIGH-DOSE FLUCONAZOLE TREATMENT IN AIDS-ASSOCIATED CRYPTOCOCCAL MENINGITIS
INSTITUTO NACIONAL DE ALERGIAS Y ENFERMEDADES INFECCIOSAS DE LOS ESTADOS UNIDOS, SOCIAL & SCIENTIFIC SYSTEMS, INC,,0 个研究点目标入组 0 人开始时间: 2010年7月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65（—）
- 性别
- All
入选标准
- •CM documented either by a positive CSF cryptococcal culture, a positive CSF India ink preparation, or a positive CSF cryptococcal antigen latex agglutination test within 7 days prior to entry. More information on this criterion can be found in the protocol.
- •CSF collection for quantitative cryptococcal culture within 72 hours prior to study entry or planned to be performed at study entry
- •HIV-1 infection documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by or within 10 days after study entry by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, by HIV-1 antigen, or by plasma HIV-1 RNA viral load. More information on this criterion can be found in the protocol.
- •Ability to take oral medications. NOTE: Administration of fluconazole tablets via nasogastric tube is permitted.
- •For patients with a co-morbid complication of HIV, including opportunistic infections, reasonable certainty that the site investigator will be able to perform CSF sampling and manage expected study drug toxicities. More information on this criterion can be found in the protocol.
- •For female participants of reproductive potential (defined as girls who have reached menarche or women who have not been post-menopausal for at least 24 consecutive months [i.e., who have had menses within the preceding 24 months, or have not undergone surgical sterilization, for example, a hysterectomy, or bilateral oophorectomy or salpingotomy]) a negative serum or urine pregnancy test result must be obtained within 2 days prior to study entry
- •All participants must agree not to participate in the conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization).
- •If participating in sexual activity that could lead to pregnancy, female study participants must agree to the simultaneous use of two forms of contraception (listed in protocol) during sexual activity, and male study participants must agree to use a condom during such sexual activity. This requirement continues while the study participant is on study treatment and for 6 weeks after fluconazole has been discontinued. More information on this criterion can be found in the protocol.
- •Study participants who are not of reproductive potential (defined as women who have been post-menopausal for at least 24 consecutive months, women who have undergone surgical sterilization [e.g., hysterectomy, or bilateral oophorectomy or salpingectomy], or men who have documented azoospermia) are eligible without the requirement to use contraceptives. More information on this criterion can be found in the protocol.
- •Willingness and ability to adhere to dose schedules and mandatory procedures
- •Measured or calculated creatinine clearance of 50 mL/min or more within 3 days prior to study entry. More information on this criterion can be found in the protocol.
- •The following laboratory values within 3 days prior to study entry: aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase less than or equal to 5 times the upper limit of normal (ULN); total bilirubin less than or equal to 2.5 times ULN; absolute neutrophil count (ANC) equal to or greater than 750/mm^3; platelet count equal to or greater than 50,000/mm^3; hemoglobin equal to or greater than 7.0
排除标准
- •Expected survival of 2 weeks or less, in the opinion of the site investigator and, if available, the primary care provider
- •For patients with a comorbid complication of HIV, anticipated difficulty, in the opinion of the site investigator, in judging response to study treatment as a result of the comorbid complication or the drugs used to treat it
- •Breastfeeding
- •prior episode of CM, either as indicated by patient or as noted in patient medical records
- •Use of certain drugs within specified time periods. More information on this criterion can be found in the study protocol.
- •For candidates who are currently taking nevirapine, the inability to discontinue nevirapine and replace it with a drug that does not have fluconazole drug interactions at or by study entry in the event they are randomized to a high-dose fluconazole treatment arm. More information on this criterion can be found in the study protocol.
- •Known allergy, sensitivity to, or intolerance of fluconazole or other imidazole or triazole compounds or to ampho B or other components of the standard of care ampho B based regimen
- •History of clinically significant cardiac disease, in the opinion of the site investigator, including symptoms of ischemia, coronary artery disease, congestive heart failure, or arrhythmia
- •ECG with QTc interval greater than 450 msec within 7 days prior to study entry. More information on this criterion can be found in the study protocol.
- •History of CNS disorder (excluding mood disorders) or concurrent CNS disorder(s) that, in the opinion of the investigator, would interfere with assessment of efficacy (e.g., ability to perform CSF sampling) such as lymphoma, neurocysticercosis, or toxoplasmosis
- •Receipt of investigational drug therapy within 30 days prior to study entry without prior approval of the A5225/HiFLAC core team
- •Active drug or alcohol use, dependence, or other conditions that in the opinion of the site investigator would jeopardize the safety of a participant in the study or would render the person unable to comply with the study plan
研究者
相似试验
招募中
1 期
High-Dose Fluconazole for the Treatment of CM in HIV-infected PeopleCTRI/2013/04/003545Division of AIDS DAIDS NIH USA Division of AIDS DAIDS NIH USA192
进行中（未招募）
不适用
A Phase II Study of Dose Density Regimen with Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days with Filgrastim Support followed by Weekly Paclitaxel in Women with Primary Breast Cancer. - NDPatients with primary breast cancerMedDRA version: 9.1Level: LLTClassification code 10006187EUCTR2010-020772-38-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
进行中（未招募）
不适用
A Dose Targeted Phase I/II Study To Evaluate The Feasibility, Safety, And Biological Effects Of Intravenous Administration of A Wild-Type Reovirus (REOLYSIN®) in Combination With Paclitaxel and Carboplatin To Patients With Advanced MalignanciesAdvanced or metastatic solid tumours that are refractory to standard therapy or for which no curative standard therapy exists and for which paclitaxel plus carboplatin is appropriate palliative chemotherapy.MedDRA version: 8.1Level: LLTClassification code 10049280Term: Solid tumourEUCTR2006-006515-76-GBOncolytics Biotech Inc
进行中（未招募）
1 期
A clinical gene therapy study with hematopoietic stem cells for the treatment of patients suffering from a malignant neoplasm of the central nervous systemGlioblastoma MultiformeEUCTR2018-001404-11-ITGENENTA SCIENCE SR21
进行中（未招募）
不适用
PHASE I / II STUDY OF SEQUENTIAL HIGH-DOSE CHEMOTHERAPY WITH STEM CELL SUPPORT IN CHILDREN YOUNGER THAN 5 YEARS OF AGE WITH HIGH-RISK MEDULLOBLASTOMAHigh-risk medulloblastomaMedDRA version: 16.0Level: PTClassification code 10027107Term: MedulloblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004842-14-FRInstitut de cancérologie Gustave Roussy